Advanced Lung Disease: Novel Therapies and Controversies Conference 2020

2nd Advanced Lung Disease: Novel Therapies and Controversies Conference is organized by Baylor College of Medicine (BCM), Michael E. DeBakey Department of Surgery at Baylor College of Medicine. This Online CME Course will be held from Dec 05 - 06, 2020.

Accreditation 
Texas Heart Institute is approved by the Accreditation Council for Continuing Medical Education to present continuing medical education for physicians. 

Credit Designation
Texas Heart Institute assigns this online CME activity for a maximum of 11.50 AMA PRA Category 1 Credits™. Physicians will be able to earn only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Credit
Successful completion of this CME activity, which involves participation in the evaluation component, allows the participant to earn up to 11.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Attendees will receive MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to proffer participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Course Description:
The Advanced Lung Disease: Novel Therapies and Controversies Conference will have appealing state-of-the-art multidisciplinary lectures centered on the conditions diagnosis, prevention, and treatment of diseases affecting the lungs, along with the cystic fibrosis, COPD, Interstitial Lung Disease, pulmonary hypertension, and adult congenital heart diseases. The course will also feature panel sessions to provide clinicians the opportunity to discuss specific treatment challenges, the role of the caregivers, transplant coordinators, and logistics of transplantation and methods that will be useful in their practices.

Advanced lung diseases affect a huge part of the population and provide significantly to morbidity and mortality. Novel therapies for diseases such as cystic fibrosis, COPD, Interstitial Lung Disease, pulmonary hypertension, and adult congenital heart diseases have furnished patients a chance at a new and healthier life. Transplantation is a significant part of the innovation for presenting these patients a new lease on life, but there are many steps and considerations along the way that can add to quality life years. The conference seeks to provide practitioners, trainees, patients, and associated staff with a look at the horizon of advanced lung therapies. Novel therapies such as ex vivo lung perfusion, airway stenting, biopsies, gene therapy, stem cells, bronchial valves, and lung volume reduction therapy will be addressed. Break out sessions will discuss the role of the caregivers, transplant coordinators, and logistics of transplantation.

Additional details will be posted as soon as information is available.